CompletedPhase 2

Methylene Blue for the Prevention of Hypotension During Hemodialysis

Brazil261 participantsStarted 2021-10-21

Plain-language summary

Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients over 18 years old * Acute kidney injury or acute-on-chronic kidney disease requiring intermittent renal replacement therapy hemodialysis * Systolic blood pressure lower than 100 mmHg or use of vasopressor * Signed informed consent Exclusion Criteria: * Pregnancy * Life expectancy less than 24 hours * Exclusive palliative or end-of-life care * RRT due to hypertensive crisis * Known allergy to methylene blue * Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency * Prior participation in the study * Acute coronary syndrome * Chronic nitrate oral use

What they're measuring

Composite Endpoint

Timeframe: 6 hours

Trial details

NCT IDNCT05092165

SponsorFederal University of São Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-16

View on ClinicalTrials.gov More Acute Kidney Injury trials